Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

the prior year quarter. Over the course of 2007, we made optional and mandatory principal repayments of term debt totaling $350.5 million using free cash flow and cash on hand.

Income taxes

Our effective tax rates for the quarter and year ended December 31, 2007 was 38.3% and 38.9%, respectively. On February 25, 2008, the Company's US operating entities entered into an Advanced Pricing Agreement ("APA") with the Internal Revenue Service ("IRS") covering the calendar years 2006 through 2010. The APA is an agreement with the IRS that specifies the agreed upon terms under which the Company's U.S. entities are compensated for services provided on behalf of its non-U.S. entities. The APA provides the Company with greater certainty with respect to the mix of its pre-tax income in the various tax jurisdictions in which it operates.

Net Income and Cash Net Income

For the quarter ended December 31, 2007, reported net income was $19.7 million, or $0.08 per share, and CNI was $73.9 million, or $0.30 per share, based on 250.5 million diluted Class A common shares outstanding. In arriving at CNI, we add back the after-tax impact of the amortization of intangible assets and the amortization and write-off of deferred financing costs. These items are tax-effected at the estimated marginal rates attributable to them. In the quarter ended December 31, 2007, the marginal tax rate associated with the amortization of intangible assets was 8.8% and the marginal tax rate for amortization and write-off of deferred financing costs was 8.9%.

Liquidity, Balance Sheet and Cash Flows

As of December 31, 2007, our cash and cash equivalents totaled $30.8 million and total debt outstanding was $1,200.2 million, a decrease of $350.5 million in total debt outstanding, compared to $1,550.7 million as of December 31, 2006. There were no borrowings outstanding under the revolving portion of our senior secured credit facility. We generated $105.8 million of cash
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 Working in collaboration ... in London , Richmond Pharmacology is the ... Phase 3 study for an investigational RNAi therapeutic being developed ... affecting the nerves and heart. Read press ... Based at St Georges University of ...
(Date:3/27/2015)... ROCKVILLE, Md. , March 27, 2015  CASI ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a commercial focus on ... the three and 12 months ended December 31, 2014.  ... of ($1.6 million), or ($0.05) per share, for the ...
(Date:3/26/2015)... 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... advanced testing solutions for the detection of foodborne ... three months and full year ended December 31, ... for the quarter ended December 31, 2014 was ... quarter of 2013 and $1.5 million for the ...
(Date:3/26/2015)... TORONTO , March 26, 2015 /PRNewswire/ - SQI ... SQIDF) announced that after dealing with certain matters, including ... of shareholders held on March 26, 2015 (the "Meeting") ... until April 8, 2015 at 11:00 a.m. ( ... Meeting has been changed from that previous disclosed. The ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... Netherlands , April 28, 2010 , Pepscan, the Netherlands ... of immune therapeutics, today,announced that it reached a partnering agreement for ... of the,agreement Pepscan will receive an undisclosed cash payment as well ... , , ...
... , S-HERTOGENBOSCH, The Netherlands , April ... novel methods in,immunotherapy with the most recent insights in oncology to develop ... , , ... Netherlands , April 27, 2010 - Immunovo BV, a new,biotechnology ...
... The Johns Hopkins University School of Medicine and The ... to advance the development and use of stem cells in therapies for a ... to use stem cells and foster joint research projects. , ... The collaborative program will encompass training for Johns ...
Cached Biology Technology:Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio 2Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio 3Immunovo BV- A New Biotechnology Company is Announced 2The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 2The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 3The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 4The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 5
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:2/25/2015)... Feb. 25, 2015  ABC Financial Services (ABC), ... the Health and Fitness Industry, today announced enhancements ... MYiCLUBonline.  The latest upgrade includes advances to the ... cardless check-in via Identity One fingerprint biometrics. The ... through interactive displays at the International Health, Racquet ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... jobs, clean energy and a more sustainable use of ... talks. During the summit, the role of Earth observation ... blueprint to rethink economic growth, advance social equity and ... in Rio de Janeiro, Brazil. ,Now, 20 years later, ...
... previously documented that substances from the South African plant ... daffodils have an effect on the mechanisms in ... has now yielded further results, since a team based ... recently shown how several South African daffodils contain plant ...
... Innes Centre is the author of a new book ... define life. http://youtu.be/urDhZkCtkvM What ... develops into an infant, a child who learns to ... For many years, scientists have generally thought these great ...
Cached Biology News:Earth observation for us and our planet 2South African daffodils may be a future cure for depression 2'Cells to Civilizations: The Principles of Change That Shape Life' 2
... PP2A1, purified Formulation: 50mM Tris-HCl, ... Brij-35, 0.2mM PMSF, 1mM benzamidine, ... Properites: PP2A1 (Protein Phosphatase 2A1) ... ammonium sulfate precipitation, QSepharose,amino-hexyl agarose, ...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
...
... Immunogen : Recombinant human HMGN2/HMG-17 ... BSA, 0.15M NaCl, 0.05% sodium ... glycerol to 30% Quality Assurance: ... acid extracts of murine 10T ...
Biology Products: